[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100368693":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":127,"collaborators":129,"id":133,"slug":134,"hasResults":135,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":135,"sex":141,"minAge":142,"maxAge":21,"enrollmentInfo":143,"targetDuration":21,"studyType":146,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":68,"whyStopped":21,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"University Hospital, Ghent","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of care - brodalumab","EXPERIMENTAL","Patients will continue to receive brodalumab according to standard care dosing regimen, i.e. loading dose first (210mg), once a week for 2 weeks (210mg), then a regular dose regimen (210mg) every 2 weeks.",[13,14],"Procedure: Venapuncture","Other: Patient questionnaires",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","Venapuncture","Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of brodalumab",[9],null,{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Patient questionnaires","The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L",[9],[27],{"name":28,"affiliation":29,"role":30},"Jo Lambert, Prof.","University Ghent","PRINCIPAL_INVESTIGATOR",[32,37],{"name":28,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","09 332 22 87","+32","jo.lambert@uzgent.be",{"name":38,"role":33,"phone":34,"phoneExt":35,"email":39},"Lynda Grine, Dr.","lynda.grine@uzgent.be",[41,58,66,77,89,102,115],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"AZ Maria Middelares","NOT_YET_RECRUITING","Ghent","Oost-Vlaanderen","9000","Belgium","BE",{"type":50,"coordinates":51},"Point",[52,53],3.71667,51.05,{"lat":53,"lon":52},[56],{"name":57,"role":33,"phone":21,"phoneExt":21,"email":21},"Linda Temmerman, Dr.",{"facility":59,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},"AZ Sint-Lucas",{"type":50,"coordinates":61},[52,53],{"lat":53,"lon":52},[64],{"name":65,"role":33,"phone":21,"phoneExt":21,"email":21},"Laurence Dierkxsens, Dr.",{"facility":67,"status":68,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"University Hospital of Ghent","RECRUITING",{"type":50,"coordinates":70},[52,53],{"lat":53,"lon":52},[73,75],{"name":28,"role":33,"phone":74,"phoneExt":35,"email":36},"09 332 22 97",{"name":76,"role":33,"phone":34,"phoneExt":35,"email":39},"Lynd Grine, Dr.",{"facility":78,"status":43,"city":79,"state":45,"zip":80,"country":47,"countryCode":48,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Private Practice Dermatology","Maldegem","9990",{"type":50,"coordinates":82},[83,84],3.44511,51.20737,{"lat":84,"lon":83},[87],{"name":88,"role":33,"phone":21,"phoneExt":21,"email":21},"Sven Lanssens, Dr.",{"facility":90,"status":43,"city":91,"state":92,"zip":93,"country":47,"countryCode":48,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"University Hospital","Leuven","Vlaams-Brabant","3000",{"type":50,"coordinates":95},[96,97],4.70093,50.87959,{"lat":97,"lon":96},[100],{"name":101,"role":33,"phone":21,"phoneExt":21,"email":21},"Tom Hillary, Dr.",{"facility":103,"status":43,"city":104,"state":105,"zip":106,"country":47,"countryCode":48,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"AZ Sint-Jan","Bruges","West-Vlaanderen","8000",{"type":50,"coordinates":108},[109,110],3.22424,51.20892,{"lat":110,"lon":109},[113],{"name":114,"role":33,"phone":21,"phoneExt":21,"email":21},"Marleen Goeteyn, Dr.",{"facility":116,"status":43,"city":117,"state":105,"zip":118,"country":47,"countryCode":48,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"AZ Delta Rembert","Torhout","8820",{"type":50,"coordinates":120},[121,122],3.10085,51.0656,{"lat":122,"lon":121},[125],{"name":126,"role":33,"phone":21,"phoneExt":21,"email":21},"Annelies Stockman, Dr.",{"type":128,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[130,132],{"name":131,"class":6},"KU Leuven",{"name":29,"class":6},"100368693","therapeutic-drug-monitoring-of-brodalumab-in-psoriasis-patients-bioloptim-bro-100368693",false,"NCT04080635","Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)","Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Brodalumab and the Development of Concentration-response Curve of Brodalumab of Psoriasis Patients.","BIOLOPTIM-BRO","Inclusion Criteria:\n\n1. Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis\n2. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study\n\nExclusion Criteria:\n\n1. Participants who have currently a predominant nonplaque form of psoriasis\n2. Participants who are pregnant, nursing or planning a pregnancy\n3. Participants who are unable or unwilling to undergo multiple venapunctures\n4. Participants who are treated according to a different dosing schedule than standard dosing of brodalumab","ALL","18 Years",{"count":144,"type":145},100,"ESTIMATED","INTERVENTIONAL",[148],"NA","Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. Within this study we aim to investigate the predictive value of early serum trough levels of brodalumab and determine the therapeutic window of brodalumab in psoriasis patients.",[151],"Psoriasis Vulgaris",[153,154,155],"Psoriasis","Therapeutic drug monitoring","Brodalumab","2024-09-05",{"date":158,"type":159},"2024-09-19","ACTUAL",{"date":161,"type":159},"2018-12-14",{"date":163,"type":145},"2024-12-31",{"name":5,"class":6},7]